Quick Summary:
In the rapidly evolving landscape of pharmaceuticals and medicine, keeping pace with the latest trends and developments is crucial for strategic business decisions. Our recently published market research report on the Global Cancer Immunotherapy Market provides a comprehensive analysis and insights expected to be pivotal for business leaders and strategists.
Estimated at US$117.5 Billion in 2022, this market is projected to surge to US$378.5 Billion by 2030, with the Monoclonal Antibodies segment alone set to reach US$266.2 Billion. In the backdrop of a post-pandemic recovery, and the emergence of the Cancer Immunotherapy market as a key player in the U.S and China. This report also details competitive insights, with data on 42 featured companies including giants like AstraZeneca and Pfizer. Stay ahead of the curve by studying industry trends, regional market growth projections, pivotal competitors, and much more in our exclusive report.
Global Cancer Immunotherapy Market to Reach $378.5 Billion by 2030
The global market for Cancer Immunotherapy estimated at US$117.5 Billion in the year 2022, is projected to reach a revised size of US$378.5 Billion by 2030, growing at a CAGR of 15.7% over the analysis period 2022-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is projected to record 16.8% CAGR and reach US$266.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Cytokines & Immunomodulators segment is readjusted to a revised 14.6% CAGR for the next 8-year period.
The U.S. Market is Estimated at $32 Billion, While China is Forecast to Grow at 21.5% CAGR
The Cancer Immunotherapy market in the U.S. is estimated at US$32 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$94 Billion by the year 2030 trailing a CAGR of 21.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 9.9% and 13.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 11.6% CAGR.Select Competitors (Total 42 Featured) -
- Advaxis Inc.
- Amgen Inc.
- Astrazeneca
- Bayer AG
- Bristol-Myers Squibb
- Celgene Corporation
- ELI Lilly and Company
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline Plc
- Immunomedics Inc.
- Janssen Global Services, LLC (Johnson and Johnson)
- Merck
- Novartis
- Pfizer
- Seattle Genetics, Inc.
- Spectrum Pharmaceuticals, Inc.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
What is the estimated value of the Global Market for Cancer Immunotherapy?
What is the growth rate of the Global Market for Cancer Immunotherapy?
What is the forecasted size of the Global Market for Cancer Immunotherapy?
Who are the key companies in the Global Market for Cancer Immunotherapy?
| Report Attribute | Details |
|---|---|
| No. of Pages | 93 |
| Published | November 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 117.5 Billion |
| Forecasted Market Value ( USD | $ 378.5 Billion |
| Compound Annual Growth Rate | 15.7% |
| Regions Covered | Global |
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- Advaxis Inc.
- Amgen Inc.
- Astrazeneca
- Bayer AG
- Bristol-Myers Squibb
- Celgene Corporation
- ELI Lilly and Company
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline Plc
- Immunomedics Inc.
- Janssen Global Services, LLC (Johnson and Johnson)
- Merck
- Novartis
- Pfizer
- Seattle Genetics, Inc.
- Spectrum Pharmaceuticals, Inc.
